Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
J Clin Oncol Pfisterer et al.
24: 4699
Publisher's Note
The October 10, 2006, article by Pfisterer et al entitled, “Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG” (J Clin Oncol doi:10.1200/JCO.2006.06.0913) was published online September 11, 2006, with errors. In Table 3, values for number of patients were inadvertently transposed with the percentage of patients. Also in Table 3, under Grades 1 and 2 of the “GC Arm,” values for the number of patients with “Alopecia” were inadvertently given in parentheses next to the percentage of patients. In Table 4, under “Carboplatin,” the values for “Overall Response Rate” were inadvertently transposed. All corrections have been made as of September 18, 2006.
|